Postoperative Pain

This study aims to compare the effectiveness of lignocaine versus 0.2% glyceryl trinitrate (GTN) ointment as postoperative analgesics in patients who have undergone hemorrhoidectomy. Background Hemorrhoids are swollen veins in the anal region, commonly treated through Milligan-Morgan hemorrhoidectomy. Postoperative pain is a major concern, affecting mobility and delaying recovery. Various treatments have been explored to alleviate post-hemorrhoidectomy pain, including anal dilatation, NSAIDs, opioids, and topical treatments like nifedipine, botulinum toxin, lignocaine, and GTN ointment. Both GTN and lignocaine have been shown to reduce pain, but the most effective and safe option is still unclear. Study Objective To compare the outcomes of lignocaine versus 0.2% GTN ointment in reducing pain and promoting wound healing in post-hemorrhoidectomy patients. Hypothesis There is a difference in the pain relief and wound healing outcomes between lignocaine and GTN ointment in hemorrhoidectomy patients. Study Design Randomized clinical trial conducted at the Department of Surgery, Mayo Hospital, Lahore. Duration: 3-6 months after synopsis approval. Sample Size: 64 patients (32 in each group). Inclusion Criteria: Age 18-60, both genders, Grade III/IV hemorrhoids, ASA grades I \& II. Exclusion Criteria: Allergies to lignocaine or GTN, pregnancy, concomitant perianal pathology, cardiovascular issues, use of nitrates or calcium channel blockers. Methods Participants will undergo hemorrhoidectomy under spinal anesthesia/saddle block/general anesthesia. Group A will receive lignocaine cream, and Group B will receive 0.2% GTN ointment post-operatively (applied 3 times daily). Both groups will receive standard postoperative care (sitz baths, stool softeners, and paracetamol for pain). Outcome Measures: Pain Score using Visual Analogue Scale (VAS) at various time points (6, 12, 24, 48, 72 hours; 7, 14, 21, and 28 days post-surgery). Time to complete wound healing (measured in days). Level of patient satisfaction after 6 weeks using a 5-point Likert scale. Data Analysis Data will be analyzed using SPSS. Descriptive statistics for quantitative variables (e.g., age, pain scores) and qualitative variables (e.g., gender, patient satisfaction). Independent t-tests will be used to compare outcomes between groups. A p-value \< 0.05 will be considered statistically significant. Patient Follow-Up Patients will be followed for 6 weeks post-surgery to monitor pain levels, wound healing, and satisfaction. Conclusion This trial aims to determine which topical analgesic-lignocaine or GTN ointment-is more effective for postoperative pain management and wound healing in hemorrhoidectomy patients.

A three-arm randomized clinical study will be conducted: * Group 1 (study group): Ridge preservation with "Pontic-shield" technique. * Group 2 (positive control): Ridge preservation with deproteinized bovine bone and porcine collagen membrane after tooth extraction. * Group 3 (negative control): Tooth extraction only (fresh socket). A cone-beam computed tomography will be performed prior to tooth extraction and 4 months postoperative. Radiographic changes between before and after intervention will be evaluated to asses the effectiveness of "Pontic-shield" technique.

Title: Efficacy of 2% Lidocaine Gel in Reducing Postoperative Pain and Analgesic Consumption Following Haemorrhoidectomy: A Randomized, Double-Blind, Controlled Trial Objective: To assess the effect of 2% lidocaine gel on postoperative pain intensity and analgesic consumption following haemorrhoidectomy. Study Design: This study is a single-center, randomized, double-blind, controlled trial. Patients will be randomly assigned in a 1:1 ratio to receive either 2% lidocaine gel or a non-anaesthetic water-based lubricant gel (control) using a computer-generated randomization list. The randomization will be stratified by hemorrhoid grade (III or IV). The study medication will be prepared by the hospital pharmacy and provided in identical, pre-filled syringes to ensure blinding of participants and investigators. Intervention: The intervention group will receive 5 mL of 2% lidocaine gel, while the control group will receive 5 mL of a non-anaesthetic water-based lubricant gel. The study medication will be applied to the perianal region three times per day for 7 days following surgery. Patients will be instructed on the proper application technique and will be provided with a diary to record the time and date of each application. Outcome Assessment: Postoperative pain will be assessed using a 100 mm visual analog scale (VAS), with 0 representing no pain and 100 representing the worst imaginable pain. Pain scores will be recorded at 12 and 24 hours, and 2, 3, and 7 days after surgery. Patients will also record their analgesic consumption in a diary, including the type, dose, and frequency of analgesics used. Postoperative complications, such as bleeding, infection, or urinary retention, will be assessed by the treating surgeon at each follow-up visit. Sample Size: A sample size of 222 patients (111 per group) was calculated based on a power of 80%, a significance level of 0.05, and an expected difference in mean VAS scores of 15 mm between the groups, with a standard deviation of 30 mm.

To understand the impact of thumb-tack needle therapy on postoperative sleep and recovery in patients who have undergone general anesthesia, and to explore the clinical significance of thumb-tack needle therapy in improving postoperative sleep quality, preventing postoperative sleep disorders, and promoting postoperative recovery

Multi-center, prospective, single-blind, randomized and parallel controlled trials are used to evaluate the role and impact of "digital chronic pain treatment system equipment" based on MR mixed reality technology in the clinical basic treatment of patients clinically diagnosed with chronic pain.

This is a multi-center, randomized, double-blind, placebo/active-controlled study. 405 subjects undergoing orthopedic surgery under general anesthesia are planned to be enrolled and randomized into the HSK21542 group, morphine group, and placebo group.

Methods: The investigators will perform a pilot prospective randomized double-blinded placebo-controlled trial of 60 patients undergoing major elective reconstructive spinal surgery to investigate the effect of a postoperative lidocaine infusion on the incidence and severity of postoperative delirium. Major spine surgery is defined as posterior spine fusions \>3 levels of instrumentation and fusion, which allows standardization of the level of surgical insult and postoperative analgesic requirements. The intraoperative anesthetic regimen will be standardized to consist of total intravenous anesthesia using sevoflurane, propofol, lidocaine and magnesium (institutional protocol), and fentanyl with boluses allowed per provider discretion. Patient recruitment, inclusion and exclusion criteria: All surgeons will be contacted before the start of the study to obtain their consent to allow their patients to be studied. The research team has successfully completed multiple National Institutes of Health (NIH) funded cohort and clinical trials at our institution with no surgeon refusing to participate. Eligible patients will be screened from the operating room roster to determine their eligibility. Patients will be contacted by phone or in person for preoperative evaluation. Please see the other section for inclusion and exclusion criteria. Sample Size Calculation: The recruitment will be consecutive patients meeting inclusion criteria. Reductions in opioid consumption by \~25% using intravenous lidocaine infusions have been shown to decrease opioid related side effects, but there is essentially no data linking a specific degree of opioid reduction to effects on delirium (46, 47). The most comparable published study to the investigators' proposal is work done by Kaba (2009) studying a lidocaine infusion for abdominal surgery where the average opioid reduction was \~50% (24mg +/-16.3 of piritramide in the placebo vs. 10.33mg +/- 10.33 in the treatment group). Assuming similar reduction in opioids of 50% and similar variance, the proposed sample size, 60 (30 per group), provides a power of 0.8 (alpha = 0.05) to detect a 25% decrease in the use of postoperative opioids. Randomization: Patients will be randomized utilizing block randomization by a random number generator into either placebo or treatment groups by the research pharmacist. The randomization scheme will be blinded to the researchers and patients. Anesthetic Management: The anesthetic management will be standardized. All patients will receive a general anesthetic to consisting of 50% oxygen and total intravenous anesthetics consisting of infusions of propofol (60-150 mcg/kg/min), lidocaine (1 mg/kg bolus, then 1.5 mg/kg/hr infusion), magnesium (30 mg/kg bolus, then 6 mg/kg/hr infusion), fentanyl (1 mcg/kg bolus, then 1 mcg/kg/hr infusion, prn boluses), and 0.3 Minimum Alveolar Concentration (MAC) of sevoflurane. Anesthesiologists will be requested to maintain the patient's arterial blood pressure to within 20% of their preoperative baseline using vasoactive agents. Patients will receive mechanical ventilation to maintain normocarbia. Intraoperative warming devices will be used to keep body temperature between 36-37˚C. Oxygen saturation will be maintained \>95%. Muscle relaxants will be used during tracheal intubation and only as clinically indicated at other time periods. All patients will be continuously monitored before the induction of anesthesia and during surgery with SEDline Brain Function Monitor (Masimo, Inc., Irvine CA), a standard monitor at our institution. Anesthesiologists will be asked to minimize electroencephalogram (EEG) burst suppression by adjusting the doses of anesthetic drugs since prior studies have suggested a relationship between burst suppression and postoperative delirium (48, 49). Postoperatively, but before discharge from the post anesthetic care unit or upon arrival to the intensive care unit, patients will be randomized to receive either placebo or a lidocaine infusion. Please see the other sections for a list of primary and secondary outcomes. Briefly the primary outcome is the effect of an intravenous lidocaine infusion on the incidence and severity of postoperative delirium. Secondary outcomes include intravenous lidocaine safety and tolerability, the effect of a lidocaine infusion on opioid usage, pain scores, analgesic satisfaction, opioid related side effects, and functional benefits. Statistical Analysis The investigators will use descriptive statistics to summarize the characteristics of the study population by treatment groups. The investigators will use an intention to treat paradigm in assessing the effect of the intervention on the outcomes of interest. Aim 1: To evaluate the safety of a continuous infusion of lidocaine in the first two days after surgery. The investigators will compare the proportion of patients that experienced at least one of the adverse events between the two groups using either the Fisher Exact Test or Chi Square Test as appropriate. Aim 2: To compare postoperative pain, and opioid usage between patients who receive placebo infusions vs. lidocaine infusions. All opioid doses will be converted to oral morphine equivalents. Specifically, hydromorphone and fentanyl doses will be converted to morphine equivalents using the conversion formula: 1.5 mg of hydromorphone = 10 mg of morphine equivalents, 0.1mg of fentanyl = 10 mg of morphine equivalents (56,57). The investigators will compare the average pain scores and opioids doses between the two treatment groups using two-sample t-tests or Mann-Whitney nonparametric tests if the data are not normally distributed. Aim 3: To compare the incidence of postoperative delirium between patients who receive placebo infusions vs. lidocaine infusions. Chi-square tests will be conducted to determine the association between lidocaine infusions and incident delirium. Aim 4: To compare the functional recovery of patients between patients who receive placebo infusions vs. lidocaine infusions. The investigators will compare the results of the 36-Item Short Form Health Survey (SF-36), Oswestry Disability Index (ODI), time to discharge, and ability to participate in physical therapy, using the two sample t-test or Mann-Whitney nonparametric test for continuous outcomes, and Fisher exact Test or Chi Square test for binary outcomes. Relevant biologic variables - All analyzes will include sex and ethnicity as covariates. Missing Data - Sensitivity Analyses to Assess the Effects of Missing Data: The investigators will use model-based methods, such as Heckman and Predicted mean matching models to determine the effect of missing observations for each of these reasons on the estimates. The investigators will track the number of missing responses for delirium, and upwardly adjust the sample size accordingly. This strategy may result in having to recruit and follow an additional subject per week in the second year of data collection, which is feasible. The investigators will conduct sensitivity analyses to determine the effect of missing data on the outcomes of interest.

The aim of the study is to check whether vagus nerve stimulation (VNS) combined with manual therapy (TM), given its neuroanatomical relationship with the structures involved in pain in the TMJ, is more effective in reducing pain, increasing joint range and increasing the quality ofthe patient lives than TM alone. The research team is made up of three physiotherapists. It has been decided to distribute the tasks as follows: * Physiotherapist 1 will be in charge of the treatment of all patients. * Physiotherapist 2 will be responsible for screening the sample and evaluating the study. * Physiotherapist 3 will be in charge of analyzing the results and statistics. This component of the team, being blinded and not knowing the group of origin of the patient, will be able to interpret the results without any type of convenience bias, showing absolutely transparency in the elaboration of the conclusions. Once the screening will be completed, the patients will be divided into two groups: an experimental group (TM + ENV) and a control group (TM + ENV placebo).The randomization will be carried out through the statistical program Epidat 4,237 9 obtaining two homogeneous groups. Each patient will be assigned a code with the aim that the physiotherapist who is in charge of the statistical analysis is not able to establish links between the data and the subjects to which it refers.

Surgical pain is one of the common complications after surgery, which seriously affects the recovery and treatment quality of patients. More than 20% of patients will suffer from postoperative chronic pain. According to the data of the National Bureau of Statistics, there are more than 70 million surgeries in China every year. Nerve block is one of the most commonly used methods for postoperative pain management in clinical practice. In recent years, the developing nerve block needle has gradually begun to be used in clinical practice. Compared with the ordinary non-developing nerve block needle, it may have a better effect on pain management after surgery, but whether it has a reduction effect on chronic pain after surgery is still unknown. The purpose of this study is to explore the effect of developing nerve block needle on postoperative pain, and to compare the difference between it and the common non-developing nerve block needle, so as to provide new ideas and methods for postoperative pain management.

The study will be divided into three parts: Part A: Single Ascending Dose - healthy participants cohorts with up to 5 dose levels. Part B: Multiple Ascending Doses - healthy participants cohorts with up to 3 dose levels. Part C: Surgical patients cohorts with up to 3 dose levels. The primary Objective is to investigate the safety and tolerability of TT5 in single and multiple ascending intravenous doses in healthy participants and in surgical patients. The Secondary Objectives are To investigate the pharmacokinetics (PK) of TT5 after single and multiple ascending intravenous doses in healthy participants and after intravenous doses in surgical patients. * To investigate the acute and chronic psychological subjective response of the healthy participants and surgical patients to TT5 * To assess the pharmacodynamics (PD) of TT5 after intravenous doses in surgical patients. Exploratory Objectives areto explore potential fluid biomarkers for TT5